Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edivoxetine in pediatric ADHD
NCT00922636Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of edivoxetine in attention deficit hyperactivity disorder (ADHD) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored Total Score at 8 weeks. Started Jun 2009; status: completed.
02
Drugs
edivoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00922636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922636.